Role of Intraoperative Beta Blocker for Morbid Obese Patients Undergoing Laparoscopic Bariatric Surgery

Lecturer of Anesthesia

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04086940

Enrollment

Registered

2019-09-12

Start date

2019-11-30

Completion date

2019-12-31

Last updated

2019-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intraoperative Awareness, Postoperative Pain

Keywords

role, INTRAOPERATIVE, beta blocker, bariatric surgery, morbid obese

Brief summary

Using esmolol during anesthetic maintenance of laparoscopic bariatric surgery significantly decreases anesthetic, analgesic requirements, postoperative pain, PNV and postoperative hypoxia.

Detailed description

Postoperative pain, nausea, vomiting (PNV) and hypoxia are common in relation to laparoscopic bariatric surgery. Sympatholytic drugs might decrease the need for intravenous or Inhalation anesthetics and opioids. In this study we wanted to analyze effects of esmolol on intraoperative anesthetic-analgesic requirements, postoperative analgesic requirements, postoperative pain, PNV and hypoxia. Methods: Sixty patients have been included. Propofol, fentanyl and rocuronium were used for induction. Study groups were as follows; group E Esmolol infusion was added to maintenance anesthetics (Sevoflurane and fentanyl), group N only Sevoflurane and fentanyl was used during maintenance. They have been monitored during the intraoperative period and postoperatively for 24 h for analgesic requirements and PNV. Visual analog scale (VAS) scores for pain was also been assessed.

Interventions

DRUGEsmolol

preventive

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Intervention model description

prospective randomized controlled study

Eligibility

Sex/Gender

ALL

Age

18 Years to 59 Years

Healthy volunteers

Inclusion criteria

* American Society of Anesthesiologists (ASA) I - II patients * age between 18-59 years * both genders * body mass index (BMI) \> 45 kg/m2

Exclusion criteria

* Patients with -hepatic * renal * cardiac * respiratory diseases * patients with a history of drug abuse or who were dependent on opioid drugs.

Design outcomes

Primary

Measure	Time frame	Description
intraoperative analgesic requirements	6 months	amount of narcotics and anesthetics needed
postoperative analgesic requirements	6 months	amount of narcotics needed

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026